This study introduced Cadd4, a peptide-based degrader developed using computer-aided drug design, which effectively reduced PCSK9 levels and increased LDL receptor expression, resulting in decreased plasma cholesterol and LDL-C levels in hypercholesterolemic mice, without liver toxicity.
5 citations
,
August 2024 in “Drug Discovery Today” This review examines advances in computer-aided drug design for targeting membrane proteins in prostate cancer but reports no new clinical results; it emphasizes the potential of structural insights and compound screening for therapeutic development.
9 citations
,
August 2023 in “Molecules” This study found that the peptides RMYYY and VMYMI displayed stronger binding energy and more frequent interactions with HPGDS compared to the native inhibitor, suggesting potential as future therapeutic drugs.
48 citations
,
August 2022 in “Chemical Biology & Drug Design” This review outlines computational strategies, including chemogenomics and drug repositioning, for coronavirus drug discovery and reports no new clinical findings; the authors highlight the advantages of these methods in rapidly identifying therapeutic candidates.
March 2016 in “Journal of Pharmacological Sciences” This discussion reviews the shift in pharmaceutical strategy towards evidence-based and structure-guided drug development, highlighting ongoing challenges and efforts in computer-aided drug design without presenting new clinical results.
